FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312095384> ?p ?o ?g. }

• W4312095384 endingPage "109553" @default.
• W4312095384 startingPage "109553" @default.
• W4312095384 abstract "Gastric cancer (GC) is characterized by aggressive tumor growth and poor prognosis. The benefits of targeted anti-programmed death receptor 1 (PD-1) monoclonal antibody combined with chemotherapy have not yet been characterized. The tumor microenvironment and circulating factors have garnered interest as possible predictors of response and prognosis. The aim of this study was to evaluate whether cytokine levels in the serum of patients were related to tumor response to anti-PD-1 monoclonal antibody combined with chemotherapy and survival in advanced GC. Preoperative serum samples were collected from patients with GC (n = 52) and healthy individuals (n = 31). The levels of 12 different cytokines were measured using a multiple microsphere flow immunofluorescence assay. The association between cytokine levels and clinical response was analyzed using nonparametric Wilcoxon matched-pair ranked tests. Progression-free survival (PFS) time for all patients was recorded via evaluation of imaging results and follow-up via telephone. Kaplan-Meier and log-rank tests were used to plot survival curves. The levels of interleukin (IL)-6, IL-1β, interferon (IFN)-γ, IL-17, and IL-12p70 in the control group were significantly lower than those in the GC group (p = 0.0002, p = 0.0065, p = 0.0003, p = 0.0303, and p = 0.0295, respectively). The level of IL-4 was significantly higher in healthy individuals than that in patients with GC (p = 0.0201). The cytokine levels in the good responder group were higher than those in the poor responder group before therapy. Patients treated with immunochemotherapy showed an overall reduction in all cytokine levels after treatment initiation. A high baseline level of IFN-γ was associated with a better prognosis. However, high IL-6 levels in patients after two cycles of immunochemotherapy indicated resistance. High IL-4 levels in patients treated with four cycles of immunochemotherapy were associated with better PFS. Our study suggests that low levels of IFN-γ before immune checkpoint inhibitor treatment may be useful for the detection of a poor immunological status. Hence, a reduction in IL-6 levels is predictive of a longer PFS, and increased IL-4 levels are predictive of a good response. IL-4 and IL-6 may, therefore, serve as promising circulating predictive biomarkers for patients who can benefit from anti-PD-1 monoclonal antibodies administered in combination with chemotherapy." @default.
• W4312095384 created "2023-01-04" @default.
• W4312095384 creator A5003490164 @default.
• W4312095384 creator A5016960570 @default.
• W4312095384 creator A5035313775 @default.
• W4312095384 creator A5038165954 @default.
• W4312095384 creator A5043179517 @default.
• W4312095384 creator A5056834769 @default.
• W4312095384 creator A5087960904 @default.
• W4312095384 creator A5089026310 @default.
• W4312095384 date "2023-01-01" @default.
• W4312095384 modified "2023-10-02" @default.
• W4312095384 title "Association between serum levels of 12 different cytokines and short-term efficacy of anti-PD-1 monoclonal antibody combined with chemotherapy in advanced gastric cancer" @default.
• W4312095384 cites W1892363013 @default.
• W4312095384 cites W1982760718 @default.
• W4312095384 cites W1995697484 @default.
• W4312095384 cites W2016783148 @default.
• W4312095384 cites W2030191482 @default.
• W4312095384 cites W2045588234 @default.
• W4312095384 cites W2076668534 @default.
• W4312095384 cites W2096846592 @default.
• W4312095384 cites W2102241357 @default.
• W4312095384 cites W2104466298 @default.
• W4312095384 cites W2104849855 @default.
• W4312095384 cites W2120929800 @default.
• W4312095384 cites W2132841383 @default.
• W4312095384 cites W2292909024 @default.
• W4312095384 cites W2613156197 @default.
• W4312095384 cites W2615907969 @default.
• W4312095384 cites W2623388110 @default.
• W4312095384 cites W2655262992 @default.
• W4312095384 cites W2867818201 @default.
• W4312095384 cites W2900046418 @default.
• W4312095384 cites W2900360032 @default.
• W4312095384 cites W2925149901 @default.
• W4312095384 cites W2950226823 @default.
• W4312095384 cites W2967144404 @default.
• W4312095384 cites W2985693568 @default.
• W4312095384 cites W3038009775 @default.
• W4312095384 cites W3093358459 @default.
• W4312095384 cites W3128646645 @default.
• W4312095384 cites W3156530501 @default.
• W4312095384 cites W3171517418 @default.
• W4312095384 cites W4239575231 @default.
• W4312095384 cites W4254345745 @default.
• W4312095384 cites W4281569520 @default.
• W4312095384 cites W4281742094 @default.
• W4312095384 doi "https://doi.org/10.1016/j.intimp.2022.109553" @default.
• W4312095384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36516540" @default.
• W4312095384 hasPublicationYear "2023" @default.
• W4312095384 type Work @default.
• W4312095384 citedByCount "2" @default.
• W4312095384 countsByYear W43120953842023 @default.
• W4312095384 crossrefType "journal-article" @default.
• W4312095384 hasAuthorship W4312095384A5003490164 @default.
• W4312095384 hasAuthorship W4312095384A5016960570 @default.
• W4312095384 hasAuthorship W4312095384A5035313775 @default.
• W4312095384 hasAuthorship W4312095384A5038165954 @default.
• W4312095384 hasAuthorship W4312095384A5043179517 @default.
• W4312095384 hasAuthorship W4312095384A5056834769 @default.
• W4312095384 hasAuthorship W4312095384A5087960904 @default.
• W4312095384 hasAuthorship W4312095384A5089026310 @default.
• W4312095384 hasBestOaLocation W43120953841 @default.
• W4312095384 hasConcept C121608353 @default.
• W4312095384 hasConcept C126322002 @default.
• W4312095384 hasConcept C143998085 @default.
• W4312095384 hasConcept C159654299 @default.
• W4312095384 hasConcept C203014093 @default.
• W4312095384 hasConcept C2776694085 @default.
• W4312095384 hasConcept C2778690821 @default.
• W4312095384 hasConcept C542903549 @default.
• W4312095384 hasConcept C71924100 @default.
• W4312095384 hasConcept C90924648 @default.
• W4312095384 hasConceptScore W4312095384C121608353 @default.
• W4312095384 hasConceptScore W4312095384C126322002 @default.
• W4312095384 hasConceptScore W4312095384C143998085 @default.
• W4312095384 hasConceptScore W4312095384C159654299 @default.
• W4312095384 hasConceptScore W4312095384C203014093 @default.
• W4312095384 hasConceptScore W4312095384C2776694085 @default.
• W4312095384 hasConceptScore W4312095384C2778690821 @default.
• W4312095384 hasConceptScore W4312095384C542903549 @default.
• W4312095384 hasConceptScore W4312095384C71924100 @default.
• W4312095384 hasConceptScore W4312095384C90924648 @default.
• W4312095384 hasLocation W43120953841 @default.
• W4312095384 hasLocation W43120953842 @default.
• W4312095384 hasOpenAccess W4312095384 @default.
• W4312095384 hasPrimaryLocation W43120953841 @default.
• W4312095384 hasRelatedWork W1969822711 @default.
• W4312095384 hasRelatedWork W1999686187 @default.
• W4312095384 hasRelatedWork W2019666956 @default.
• W4312095384 hasRelatedWork W2036403810 @default.
• W4312095384 hasRelatedWork W2049834980 @default.
• W4312095384 hasRelatedWork W2063428357 @default.
• W4312095384 hasRelatedWork W2073840950 @default.
• W4312095384 hasRelatedWork W2340284051 @default.
• W4312095384 hasRelatedWork W4211176747 @default.
• W4312095384 hasRelatedWork W4293213287 @default.
• W4312095384 hasVolume "114" @default.

• next